Preclinical, in vitro/murine; clinically advanced miRNA mimic relevant to oncology—TargomiRs/mesomiR-16 (miR-16 mimic in EGFR-targeted minicells, EnGeneIC) completed Phase I in malignant pleural mesothelioma and NSCLC (NCT02369198, 2014–2017) with acceptable safety and disease stabilization signals, but no further development or MM trial as of 2025. Here, EGFR is linked to non-small cell lung carcinoma.